In this study, we want to find out if a combination of medications (Sacituzumab Govitecan and Pembrolizumab) can improve outcomes and delay the return of cancer when compared to standard treatment. This study is for patients with triple-negative breast cancer (TNBC) who still have detectable disease after initial treatment and surgery.
At each visit, you will meet with a member of the study team to review your medications, any symptoms you may be experiencing, and receive a brief examination. The study also involves several blood draws, questionnaires, administration of intravenous drugs, possibly also oral drugs to take at home, 1 ECG and 2 ECHO scans, and tissue from initial and surgical biopsies.
UNC Rex Cancer Center
2901 Blue Ridge Rd, Raleigh, NC 27607, USA
Amanda Sherrod
UNC Hospitals - Rex
Clinical or Medical
Interventional
Cancer (Breast)
23-0652
Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.
Questions?
